Harbour BioMed, Vir to develop new therapies

By The Science Advisory Board staff writers

August 24, 2020 -- Harbour Biomed (HBM) and Vir Biotechnology have partnered to research and develop novel immuno-oncology and infectious disease therapies.

The partnership will leverage the scientific expertise at both companies in order to develop immunotherapies for patients with cancer and infectious disease. It will also utilize HBM's Harbour Mice technology to generate antibodies for the experiments.

Companies work to develop combo mAb, NK cell COVID-19 therapy
A new research project is bringing together universities and pharmaceutical companies to collaborate on the development of a combination of a monoclonal...
AbbVie licenses antibody technology for COVID-19
AbbVie, Harbour BioMed, Utrecht University, and Erasmus Medical Center announced that they have entered into a collaboration to develop a novel antibody...
Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents...
Generation Bio, Vir partner for mAbs against COVID-9
Generation Bio and Vir Biotechnology have agreed to collaborate on research into the use of monoclonal antibodies against the SARS-CoV-2 virus that causes...
Xencor, Vir partner on COVID-19 antibodies research
Biopharmaceutical companies Xencor and Vir Biotechnology have entered into a technology licensing agreement to develop potential antibody-based treatments...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter